Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Tables)

v3.21.2
Stockholders Equity (Tables)
 9 Months Ended
Sep. 30, 2021
Stockholders Equity (Tables) [Line Items]  
Schedule of outstanding warrants to purchase Common Stock [issued to shareholders]
Warrant   Issuance Date   Expiration
Date		   Exercise
Price
Per Share		     Number of
Shares of
Common Stock
Underlying
Warrants		  
Private Placement Warrants   IPO (December 13, 2018)   December 13, 2023     11.50       2,900,000  
Public Warrants   IPO (December 13, 2018)   October 28, 2024     11.50       3,500,000  
 2021 Registered Direct Offering Warrants   SPA (July 28, 2021)   January 28, 2027     5.00       2,812,501  
                      9,212,501  

 
Schedule of black-scholes option-pricing model
    Nine Months Ended
September 30,		  
    2021     2020  
Underlying value of Common Stock ($)     7.02       5.59-6.21  
Exercise price ($)     7.02       5.59-6.21  
Expected volatility (%)     85.0       85.0  
Expected terms of the option (years)     6.11       6.25  
Risk-free interest rate (%)     1.17       0.37-0.52  

 
Schedule of options granted to purchase common stock
    For the Nine Months Ended
September 30, 2021		  
    Number of
Options		     Weighted
Average
Exercise Price		     Aggregate
Intrinsic
Value		  
Outstanding at the beginning of period     3,569,766       3.12       12,338  
Granted     985,530       7.02          
Forfeited     (116,235 )     4.72          
Exercised     (79,545 )     1.52          
Outstanding at the end of period     4,359,516       3.99       9,380  
Exercisable at the end of period     2,354,505                  
Weighted average remaining contractual life of outstanding options – years as of September 30, 2021     7.43                  

  
Schedule of share-based payment expenses
    Nine Months Ended
September  30,		  
    2021     2020  
Research and development expenses, net     1,539       1,345  
General and administrative     1,113       783  
      2,652       2,128  

 

    Three Months Ended
September  30,		  
    2021     2020  
Research and development expenses, net     581       843  
General and administrative     446       271  
      1,027       1,114  
Warrant [Member]  
Stockholders Equity (Tables) [Line Items]  
Schedule of outstanding warrants
Warrant   Issuance Date     Expiration
Date		   Exercise
Price
Per Share  		     Number of
Shares of
Common Stock
Underlying
Warrants  		  
Private Warrants issued to Yeda (see 1 below)    May 11, 2017   May 11, 2025    
  (*
 )    
-
  
Private Warrants issued to scientific founders (see 2 below)    November 27, 2017        
-
       2,974  
                      2,974